Hello — I’m Dr. Khushbukhat Khan, PhD in Cancer Biology.

I help biotech companies, health-tech startups, and research teams translate cancer biology research into clinically relevant and commercially viable products, with a focus on early-stage development, translational strategy, and evidence generation.

With 5+ years of experience across cancer biology, bioinformatics, and translational research, I work at the interface of preclinical discovery and early clinical development, helping teams structure scientifically sound, regulatory-aware, and investment-ready development pathways.

I have supported 10+ biotech startups in designing research strategies, developing product roadmaps, setting up experimental frameworks, and executing translational programs

WHAT SUPPORT I PROVIDE:

– Oncology research strategy (target → validation → development)
– Preclinical study design experimental planning
– Mechanism-of-action evidence generation frameworks
– Gono-go decision support for early-stage assets
– Early clinical trial design (Phase 0 I exploratory)
– Protocol development Biomarker-driven trial strategy
– Preclinical → clinical transition planning
– Regulatory IRB documentation support
– Grant writing research proposals
– Investor decks scientific evidence briefs
– Manuscripts, publication strategy scientific communication
– Biotech health-tech RD product development strategy
– Lab setup, experimental workflow design scientific due diligence support

THOUGHT LEADERSHIP
– 70+ publications in peer-reviewed journals
– 4 book chapters
– Co-editor: Precision Oncology and Nanotheragnostic (Elsevier)
– Editorial Board: BMC Cancer, Discover Oncology (Springer Nature)
– Guest Editor: Frontiers in Oncology

MISSION
Building a platform where academia, industry, and healthcare collaborate to accelerate cancer prevention and evidence-based innovation.

CURRENT FOCUS
I am particularly focused on:
– Translating cancer biology into actionable early-stage interventions
– Improving success rates of oncology programs through better preclinical and early-phase design
– Exploring preventable causes of cancer through evidence-based strategies

Open to Collaborate

Hospitals • Universities • Pharma • Biotech • Health-tech
(Prevention Translational research Evidence generation)